Document is current
Any future updates will be listed below
-
Authors
Reilly, Aoife
Deguise, Marc-Olivier http://orcid.org/0000-0002-3802-1195
Beauvais, Ariane
Yaworski, Rebecca
Thebault, Simon
Tessier, Daniel R.
Tabard-Cossa, Vincent http://orcid.org/0000-0003-4375-717X
Hensel, Niko
Schneider, Bernard L. http://orcid.org/0000-0001-5485-8748
Kothary, Rashmi http://orcid.org/0000-0002-9239-7310
-
Funding
Funding for this research was provided by:
Muscular Dystrophy Association (575466)
Muscular Dystrophy Canada
Gouvernement du Canada | Canadian Institutes of Health Research (PJT-156379)
- License Information
-
More Information
Article History
Received: 21 January 2022
Revised: 6 April 2022
Accepted: 7 April 2022
First Online: 25 April 2022
Competing interests
: R.K. received honoraria and travel accommodations from Roche as an invited speaker at their global and national board meetings in 2019. R.K. and the Ottawa Hospital Research Institute have a licensing agreement with Biogen for the <i>Smn</i><sup><i>2B/−</i></sup> mouse model. MOD received honoraria and travel accommodations from Biogen for speaking engagements at the SMA Summit 2018 held in Montreal, Canada and SMA Academy 2019 held in Toronto, Canada. These COIs are outside the scope of this study. All other authors have no competing interests to declare.
